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ABSTRACT
Affecting approximately up to 10–40% of all cancer patients, the prognosis for patients suffering from meta-
static brain tumours is poor. Treatment of these metastatic tumours is greatly hindered by the presence of the 
blood brain barrier which restricts the overwhelming majority of small molecules from entering the brain. A 
novel approach to overcome this barrier is to target receptor mediated transport mechanisms present on the 
endothelial cell membranes, in particular the transferrin receptor. Given their specificity, safety profile and 
stability, nucleic acid-based therapeutics are ideal for this purpose. This review explores the development of 
bifunctional aptamers for the treatment of brain metastases.
KEYWORDS: Blood-brain-barrier, transferrin receptor, brain metastases, aptamers, bifunctional aptamer, drug 
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BRAIN METASTASES: PREVALENCE, PROGNOSIS 
AND TREATMENT
Classified as the most frequent cancer in the central nerv-
ous system, brain metastases (BMs) are ten more com-
mon than primary brain tumours and are associated with 
an extremely poor prognosis. Studies investigating the 
incidence of brain metastases are lacking, with reported 
percentages of patients diagnosed varying from 10–40% 
and therefore an exact incidence in not known (Walbert 
et al, 2009; Fortin, 2012; Singh et al, 2014). This is further 
complicated by the fact that some patients remain undi-
agnosed due to being asymptomatic or the disease has 
progressed too far and diagnosis would not alter their 
care (Murrell et al, 2017). This is demonstrated by the 
frequency of brain metastases in autopsy studies being 
higher than those reported in population studies (Nayak 
et al, 2012). While advances in cancer treatment have 
led to an increase in progression free survival of primary 
malignancies, the battle for many cancer patients is not 
over following the release of recent epidemiological data 
which highlighted an increase in the incidence and preva-
lence of brain metastasis (Langley et al, 2013; Singh et al, 
2014). While increasing the length of the patients’ lives, 
these treatments in turn allow greater time for metastasis 
to occur. This increase in incidence may also be attributed 
to advances in imaging and diagnostic techniques (Nayak 
et al, 2012). Of all the primary tumour types, lung, breast, 
melanoma, renal and colorectal have the highest tendency 
to metastasize to the brain (Table 1) (Soffietti et al, 2012; 
Singh et al, 2014).
The burden of this disease is further exemplified by the fact 
that median survival time is merely measured in months 
(Singh et al, 2014). The main objective when treating BMs 
is to maximise the patient’s survival and functional state, 
without compromising neurological status. To achieve this, 
treatment protocols are based around multiple factors, 
including age, health status, systemic disease burden, num-
ber of lesions and their location (Hardesty et al, 2016). Tak-
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ing these factors into account, treatment generally revolves 
around a multi-modality strategy utilising a combination 
of treatment options, including surgical resection, whole 
brain radiation therapy, stereotactic radiotherapy and tra-
ditional chemotherapy. While each of these treatments 
possess limitations, systemic treatments such as chemo-
therapy have the poorest response rate, partly explained 
by the presence of the blood brain barrier (BBB), a highly 
restrictive barrier which limits the movement of 98% of 
small molecules from entering the brain and disrupting 
homeostasis (Gabathuler, 2010).
INFLUENCE OF THE BLOOD-BRAIN-BARRIER 
ON THE TREATMENT OF BRAIN METASTASES
The human brain requires a precise microenvironment 
to function optimally. This environment is provided and 
maintained through the defined function of the BBB. 
This highly impermeable barrier plays a key role in brain 
homeostasis by segregating the brain from the blood 
impeding the influx of blood-borne molecules (Ballabh 
et al, 2004; Abbott et al, 2010). Because of this restrictive 
barrier, the availability of systemic treatments for BMs is 
greatly reduced compared with the available treatments 
for extracranial cancers. However, it is important to con-
sider that majority of brain macro-metastases (metastases 
greater than 1mm in diameter) show signs of BBB disrup-
tion, suggesting it may not be the factor hindering suc-
cessful treatment with chemotherapy (Grossi et al, 2001; 
Preusser et al, 2018). This is evident from the fact that in 
some studies, BMs have demonstrated similar responses 
to systemic chemotherapy as other metastatic sites (Grossi 
et al, 2001; Edelman et al, 2010; Barlesi et al, 2011). How-
ever, the question then arises as to whether this barrier 
breakdown allows sufficient chemotherapeutic concentra-
tions to enter the brain. Furthermore, this breakdown is 
only observed for macro-metastases, with barrier integrity 
still observed in the presence of micro-metastases (Grossi 
et al, 2001).
Structure and the function of the blood-brain-barrier
Present at all levels of the vascular tree, the BBB is com-
posed of endothelial cells lining the brain vasculature cou-
pled with surrounding astrocytes and pericytes (Figure 1). 
Forming the morphological basis of the BBB, brain 
endothelial cells are phenotypically dissimilar to those 
of the peripheral circulation (Bernacki et al, 2008). Brain 
endothelial cells are characterised by their highly polarised 
tight junctions connecting them to adjacent cells. This junc-
tion, in combination with minimal pinocytic vacuoles, limits 
Figure 1. Cellular components of the BBB. Blood vessels of the brain are lines with polarised endothelial cells connected via tight and 
adheren junctions. On the abluminal side of the barrier these cells are lined by surrounding astrocytes and pericytes.
Table 1. Common primary sources of brain metastasis.
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the free transport of molecules into the brain (Deeken et al, 
2007; Daneman, 2012).
The junctional complexes present between adjacent 
endothelial cells of the brain microvessels are the most 
important factors responsible for the impermeable nature 
of the BBB (Bernacki et al, 2008). Two main types of junc-
tional complexes are present between the endothelial 
cells, tight (TJ) and adheren junctions (AJ) (Figure 2), that 
together determine the overall paracellular permeability 
of the BBB. Composed of an intricate balance of cyto-
plasmic and transmembrane proteins linked to an actin 
cytoskeleton, the TJs of the BBB create a rate-limiting bar-
rier to paracellular diffusion of solutes (Huber et al, 2001). 
Structurally, these junctional complexes form a series of 
multiple barriers being formed of a continuous network 
of intramembrane strands of parallel proteins (Figure 2) 
(Huber et al, 2001; Luissint et al, 2012). Three key inte-
gral proteins constitute the transmembrane component of 
these TJs, occludin, claudin and junctional adhesion mol-
ecules. Together, these proteins create the primary seal 
of TJs through the formation of dimers and connection 
to their counterpart on adjacent endothelial cells (Huber 
et al, 2001; Luissint et al, 2012). While these transmem-
brane proteins are essential for TJ composition and func-
tion, several additional cytoplasmic proteins are required 
for the full function of the complexes. Numerous acces-
sory proteins are crucial in providing structural support 
for TJs. Of these, zonula occluden (ZO) proteins are of the 
most importance. Linked to the cytoplasmic C-terminal of 
both claudin and occludin, ZO proteins link these trans-
membrane proteins to an actin skeleton, providing struc-
tural and functional integrity to the endothelium (Abbott 
et al, 2010). While the TJs of the BBB limit the diffusion of 
solutes, AJs provide structural support, holding adjacent 
endothelial cells together (Figure 2). Spanning the inter-
cellular cleft between endothelial cells, cadherin proteins 
bridge neighbouring endothelial plasma membranes via 
their homophilic interactions (Huber et al, 2001; Meng 
et al, 2009). Similar to TJs, cytoplasmic catenin proteins 
play an analogous role to ZO proteins, intracellularly link-
ing cadherins to the cytoskeleton (Gloor et al, 2001; Huber 
et al, 2001).
TRANSPORT SYSTEMS OF THE BLOOD-BRAIN-BARRIER
The highly polarised nature of the BBB endothelial cells and 
the overall tightness of the structure, restricts the trans-
port of molecules greater than 500 daltons into the brain 
(Daneman, 2012). This results in the prevention of an over-
whelming majority of small molecules from crossing the 
BBB (Gabathuler, 2010). In addition to this, the few drugs 
capable of crossing the barriers are actively pumped back 
out by protein efflux transporters present on the endothe-
lial cells membranes. The overall restrictive nature of this 
barrier tightly regulates the delivery of vital nutrients, min-
erals and molecules essential for the maintenance of brain 
homeostasis. Though the restrictive architecture of the 
Figure 2. Junctional complexes of the BBB tight junctions. The BBB consists of a physical and physiological barrier whereby the physi-
cal component is comprised of TJs and AJs, which together restrict the movement of molecules from the blood to the brain. Gener-
ated through three integral transmembrane proteins, occludin, claudin and junctional adhesion molecules, interconnected with 
accessory proteins, TJs limit the paracellular diffusion of solutes. AJs provide structural support for the BBB through holding adjacent 
endothelial cells together.
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BBB tightly regulates the influx of hydrophilic substances 
essential for the maintenance of brain homeostasis from 
the blood to the brain, the presence of carrier and recep-
tor mediated transport systems (Figure 3) promotes the 
transportation of molecules essential for cerebral function 
(Svetlana et al, 2011).
ATP- binding cassette transporter efflux
The protective role of the BBB is further enhanced by 
ATP-binding cassette transporter efflux proteins. Present 
on the abluminal and luminal sides of the endothelial 
cells, these transporters have a dual role, firstly to pro-
tect the brain microenvironment from the influx of neu-
rotoxins and secondly, restrict the access of therapeutics 
(Figure 3B) (Miller, 2010). Identified as playing a key role in 
the chemo-resistance of cancer cells, these efflux pumps 
have a similar effect in the endothelial cells of the BBB. 
Their presence has significant implications on the systemic 
treatment options available for patients suffering from 
BMs, as they efficiently remove drugs before a therapeuti-
cally relevant dose can be achieved. This is evident in the 
case of lipid-soluble drugs which would be expected to 
easily diffuse across the BBB but due to these transporters, 
have lower permeability than that predicted by their lipid 
solubility (Deeken et al, 2007). Numerous efflux transport-
ers have been identified on the BBB endothelium, includ-
ing MDR1, multidrug resistance proteins and OATP/OCTP 
organic anion and cation transporters (Deeken et al, 2007; 
Cioni et al, 2012).
Transport proteins
The highly restrictive nature of the BBB results in the 
majority of small polar molecules being incapable of dif-
fusing into the brain (Figure 3C). These molecules include 
glucose, amino acids, nucleosides and many other mol-
ecules. Given the essential roles these molecules play in 
cell growth and metabolism, it is essential for them to 
be transported across the BBB. This is achieved through 
the presence of carrier mediated transport proteins pre-
sent on both the luminal and abluminal membranes of 
the endothelial cells of the BBB. These proteins mediate 
the bi-directional movement of these molecules between 
the blood and the brain. Examples of these transporters, 
include the GLUT1 glucose transporters, LAT1 large neutral 
amino-acid transporters, CNT2 concentrative nucleotide 
adenosine transporters and OATP/OCTP organic cation and 
anion transporters.
Receptor mediated transcytosis
Transcytosis across the BBB via endocytic mechanisms 
is the main route by which large macromolecules enter 
the brain microenvironment (Figure 3D). In this mecha-
nism, following ligand binding to the receptor on the api-
cal membrane, the membrane invaginates the complex, 
Figure 3. Mechanisms of transport across the BBB. A number of transport processes can be distinguished: Passive diffusion, a 
mechanism driven by a concentration gradient mainly involving small hydrophobic molecules. ATP- binding cassette Transporter 
efflux, transporters which play a critical role in preventing neurotoxic substances from entering the brain. Carrier mediated 
transport, transport mechanisms of many essential polar molecules. Receptor mediated transcytosis, requires receptor binding 
of ligand and can transport a variety of macromolecules Adsorptive transcytosis, a non-specific transport mechanism dependant 
on charge. Paracellular aqueous pathway, transport limited to water soluble molecules.
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forming an intracellular vesicle, where it is shuttled to 
the basolateral membrane and the contents of the vesi-
cle are released (Lajoie et al, 2015). An example of recep-
tor-mediated transcytosis (RMT) operating in the BBB is 
the transport of iron loaded transferrin (Tf). Playing an 
essential role in mitochondrial energy generation, neuro-
transmission, oxygen transport, and cellular division, the 
transport of iron into the brain microenvironment is criti-
cal for normal brain function (Ponka et al, 1999; McCarthy 
et al, 2015). Upon association with the transferrin recep-
tor (TfR) at the apical endothelial cell surface, the iron-
bound Tf is internalised and following a drop in pH (pH 7.4 
to 6.0), iron is released into the early endosome, where it 
is then released into the brain following the fusion of the 
vesicle with the basolateral membrane (Ponka et al, 1999; 
Georgieva et al, 2014).
Adsorptive mediated transcytosis
Adsorptive mediated transcytosis is the main route by 
which large positively charged macromolecules non-spe-
cifically enter the brain microenvironment (Figure 3E). This 
process is initiated by the adsorption of cationic molecules 
on the negatively charged domains on the apical surface 
of the endothelial cell membranes (Lajoie et al, 2015). This 
adsorption triggers the endocytosis process and similar to 
RMT, the membrane invaginates this complex forming an 
intracellular vesicle, where it is shuttled to the basolateral 
membrane and the contents of the vesicle are released 
(Lajoie et al, 2015).
METHODS TO OVERCOME THE BLOOD-BRAIN-
BARRIER
Given the significant need to increase cytotoxic therapy 
accumulation in metastatic brain tumours, there are 
numerous strategies to enhance delivery which could be 
investigated. These approaches include hijacking recep-
tor mediated transport mechanisms present on the BBB 
endothelium, bypassing the BBB through local delivery 
of therapeutic agents, the delivery of chemotherapeutics 
simultaneously with drug transport inhibitors and disrup-
tion of the barrier (Table 2).
Table 2. Summary of advantages and disadvantages of the methods to overcome the BBB
Method Description Advantages Disadvantages
Direct  
Administration
Delivery in this manner is  
achieved through intrathecal  
delivery.
▪  Lower required dose
▪  Only the brain is exposed  
to indiscriminate cytotoxic  
agent
▪  Highly invasive method
▪  Non-targeted drug  
dispersion
▪  Ineffective volume  
of drug distribution
▪  Potential to cause  
significant neurotoxic  
and cognitive damage
Chemical barrier  
disruption
Injection of a vasoactive  
agent generates a temporary  
inflammatory reaction in the  
endothelial cells, disrupting  
the TJs
▪  Non-invasive
▪  Increases drug  
concentration capable  
of entering the brain
▪  Non-targeted drug  
dispersion through  
body and brain
▪  Potential for drugs to  
reach neurotoxic levels
▪  Influx of neurotoxic  
blood-borne molecules
Osmotic barrier  
disruption
Endothelial cells are exposed  
to hypertonic solution,  
causing them to shrink,  
placing significant stress  
on the TJs causing them  
to open.
▪  Non-invasive
▪  Increases drug  
concentration capable  
of entering the brain
▪  Non-targeted drug  
dispersion throughout  
the body and in the brain
▪  Negative effects on  
blood pressure and  
fluid balance
▪  Potential for cytotoxic  
agents to reach  
neurotoxic levels
▪  Global barrier disruption





Microbubbles are injected  
into patient and when they  
m pass through the  
ultrasound field directed at  
the tumour site, they  
oscillate at the same,  
causing them to expand  
and contract, disrupting  
the TJs.
▪  Non-invasive
▪  Barrier disruption occurs  
at the tumour site
▪  Increases concentration  
of chemotherapeutic  
capable of entering the  
brain
▪  Non-targeted drug  
dispersion throughout  
the body and in the brain





Therapeutic modalities are  
substrates developed which  
are substrates for influx  
transporters present on  
endothelial cell membranes.
▪  Non-invasive
▪  BBB remains intact
▪  Increased drug delivery  
as a result of  
circumventing efflux  
capacity of the BBB
▪  Non-targeted drug  
dispersion in the brain
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Hijacking transport mechanisms
A promising technique being developed which could be 
employed to deliver chemotherapeutics and treat BMs 
is the development of therapeutic modalities which are 
substrates for influx transporters present on endothelial 
cell membranes. Through designing drugs and transport 
modalities for these transporters they attain the ability to 
pass through the BBB without disruption, in addition to 
circumventing the efflux capacity of the BBB, ultimately 
increasing drug delivery to brain (Deeken et al, 2007).
Given the strong expression of the TfR on the BBB, numer-
ous therapeutics have been generated in an attempt to 
improve the therapeutic treatment of Alzheimer’s disease 
and glioblastoma (Xu et al, 2011; Yu et al, 2011). In 2011, Xu 
et al reported the anti-tumour effects of an anti-Tf mono-
clonal antibody on glioma cells in vitro, both in combination 
with a chemotherapeutic drug and alone (Xu et al, 2011). 
Interestingly, results from this study showed that the anti-
body alone had an anti-proliferative effect through induced 
S phase accumulation and apoptosis, and when used in 
combination with the chemotherapeutic the effect was fur-
ther enhanced, which suggested that combination therapy 
was more effective (Xu et al, 2011). In the same year, Yu et al 
reported the development of a bi-specific antibody capable 
of exploiting the TfR and targeting an enzyme associated 
with Alzheimer’s disease (Yu et al, 2011). The reduction in 
amyloid-β production following antibody administration, 
demonstrates that, through targeting the TfR pathway, a 
therapeutically relevant concentration of antibody can be 
delivered across the BBB in an in vivo model (Yu et al, 2011). 
An important observation arose from this report in regards 
to antibody affinity toward the TfR. It was discovered that 
the antibody required a lower binding affinity (~100nM), in 
order for it to be released from the TfR upon internalization, 
an important observation for future research and develop-
ment of this method (Yu et al, 2011). Recently, the ability of 
other antibody formats, such as single-chain fragment vari-
ables (scFv), to transcytose the BBB have been investigated 
(Chandramohan et al, 2013; Wang et al, 2014; Bao et al, 
2016; Kim et al, 2018). Through employing a scFv of an anti-
human TfR monoclonal antibody Kim et al. were able to 
develop BBB crossing nucleic acid encapsulating liposomes 
with the ability of modulating neuronal gene expression 
and apoptosis (Kim et al, 2018). Numerous fragments have 
also shown therapeutic potential for targeting glioblastoma 
in vivo, however results thus far have only been generated 
using highly invasive delivery techniques, including convec-
tion enhanced delivery and intracerebral injection (Chan-
dramohan et al, 2013; Wang et al, 2014; Bao et al, 2016).
Given the promise behind this delivery technique, it may 
be a suitable method for the treatment of BMs. However, 
given the severe side effects and immunological risk anti-
bodies pose and the invasive delivery methods used thus 
far for scFv’s a novel therapeutic strategy is required.
APTAMERS AS A TARGETED NOVEL DRUG DELIVERY 
METHOD FOR THE TREATMENT OF BRAIN 
METASTASES
Nucleic acid-based aptamers are an emerging field of 
novel therapeutics which have the potential to be devel-
oped for the treatment of BMs. Aptamer development 
began in 1990, following the ground breaking develop-
ment of the polymerase chain reaction, which had a key 
influence on molecular biology (Mayer, 2009). This devel-
opment involved the influence of three independent 
research groups, who each contributed independently 
by documenting the isolation of a single stranded nucleic 
acid with pre-defined functions (Ellington et al, 1990; Rob-
ertson et al, 1990). Following their discovery of RNA mol-
ecules that bound to an organic dye, Ellington and Szostak 
defined the molecules as aptamers, a word chimera built 
from the Latin ‘aptus’ (to fit) and the Greek ‘meros’ (part) 
(Ellington et al, 1990; Mayer, 2009). Often referred to as 
chemical antibodies, aptamers are chemically synthesised 
molecules that bind to their target through shape recogni-
tion, like antibodies.
Systematic Evolution of Ligands by Exponential Enrich-
ment
The chemical generation of aptamers, a process known as 
the systematic evolution of ligands by exponential enrich-
ment (SELEX), is a well-established technology, which gen-
erates oligonucleotides with the highest possible target 
affinity (Figure 4). A combinatorial chemistry technique 
of screening, SELEX involves iterative rounds of partition 
and amplification of a random large library of oligonu-
cleotides containing 1014–1016 candidates (Qu et al, 2017). 
Initially, the target ligand is incubated with the large ran-
dom library, followed by the removal of non-binding and 
low-binding sequences, and then the bound sequences 
are eluted and amplified using PCR to be used in sub-
sequent rounds of selection (Tuerk et al, 1990; Stolten-
burg et al, 2007). Subsequent to the first few rounds of 
positive selection, negative selection steps are introduced 
into the cycle to eliminate non-targeted sequences. After 
the final round of selection, the generated aptamers are 
sequenced and characterised. Based on this technology, 
aptamers can be developed to bind to a number of dif-
ferent classes of targets, from single molecules to com-
plex targets such as whole cells or organisms (Stoltenburg 
et al, 2007). Indeed, the ability to generate cell-specific 
aptamers through employing whole live cells as targets, 
could be employed for the treatment of brain metasta-
ses. Through targeting metastatic tumour cells rather 
than primary tumour cells, the phenotypic traits of the 
metastatic cells could be exploited to increase selectivity. 
While the selection process is characterised by repetition 
of the aforementioned steps, there is no standardised 
SELEX protocol, and the overall design of the selection 
conditions depends on a number of factors, mainly the 
library, the target, desired features, and aptamer applica-
tion (Stoltenburg et al, 2007).
Advantages and limitations of aptamers
As aptamers function by molecular recognition, they can 
be developed for therapeutic applications with the same 
intended function as antibodies, such as drug delivery 
vehicles. Though analogous to their protein counterparts 
in regards to target recognition and application, aptam-
ers possess numerous key advantages over antibodies 
and antibody fragments, the main being their size, pro-
duction process and cost, stability and nucleic acid struc-
ture (Keefe et al, 2010). The significantly smaller size of 
aptamers to antibodies (6–10kDa vs 150kDa) allows for 
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greater tissue penetration and permits their access to 
biological compartments inaccessible to antibodies (Zhou 
et al, 2012). However, given the comparable size of anti-
body fragments (27kDa), similar tissue penetration pat-
terns would be observed (Razpotnik et al, 2017). Small size 
may also be viewed as a limitation as it restricts circulatory 
half-life due to filtration through the reticuloendothelial 
system, which has a cut-off threshold of 30–50kDa (Keefe 
et al, 2010). To address this issue, aptamers and antibody 
fragments can be conjugated with bulky molecules, such 
as polyethylene glycol or cholesterol, to increase their size 
(Keefe et al, 2010; Razpotnik et al, 2017). The chemical 
generation of aptamers guarantees consistent production 
and is relatively inexpensive in comparison to the laborious 
and inconsistent in vitro or in vivo production of antibodies 
and antibody fragments (Zhou et al, 2017). The nucleic acid 
composition of the aptamers offers significant advantage 
over the protein nature of antibodies in regards to struc-
tural stability. While antibodies are irreversibly denatured 
when exposed to varying physical conditions such as tem-
perature and pH, aptamers are insensitive to these changes, 
retaining the ability to return to their original confirmations 
following exposure (Adler et al, 2008). However, in regards 
to serum stability and in vivo half-life, this composition 
can be a disadvantage, as both unmodified RNA and DNA 
are highly susceptible to nuclease degradation. Numerous 
modifications can be introduced to address this, majority of 
which concern the sugar component of the nucleic acid, as 
the 2’-position of it is the natural site of nucleophilic attack 
(Mayer, 2009). These modifications include the incorpora-
tion of fluoro, amino, alkyl and thio groups at this position 
and the inclusion of locked and unlocked nucleic acids (Ni 
et al, 2017). Issues arise when introducing these modifica-
tions along with the polymers, as introduction Post-SELEX 
has the potential to influence binding affinity and selectiv-
ity. Therefore, following modification, it is essential to reas-
sess these characteristics. While it is thought that aptamers 
lack immunogenicity given their nucleic acid nature, they 
are synthetic and comprised of CpG motifs and other 
immunostimulatory sequences and can therefore poten-
tially activate the innate immune system in vivo (Avci-Adali 
et al, 2013). Depending on the intended application of the 
aptamer, this would need to be assessed prior to in vivo 
application.
Applications of aptamers in the treatment of brain 
metastases 
Given their similarity to antibodies, aptamers can be 
employed in a range of pharmacological areas, including 
applications such as drug discovery, diagnostics, molecular 
imaging, drug delivery vehicles and as protein inhibitors or 
modulators. At present, only one aptamer, Macugen, has 
been approved by the US Food and Drug Administration 
(FDA) while several aptamers are currently in clinical tri-
als (Ruckman et al, 1998; Bell et al, 1999; Sundaram et al, 
2013; Yu et al, 2016b). Approved by the FDA in 2004 Macu-
gen is used for the treatment of macular degeneration, 
functioning through the inhibition of an isoform of vascular 
endothelial growth factor, thus ultimately inhibiting angio-
genesis (Ruckman et al, 1998; Bell et al, 1999).
Figure 4. The Systematic Evolution of Ligands by Exponential Enrichment (SELEX). Initially a desired target ligand is exposed to a ran-
dom pool of chemically synthesised oligonucleotides. Low and non-binding species are removed while the binding species are eluted 
and amplified using PCR subsequent to the next selection round. Prior to incubation with the target throughout selection, sequences 
are subjected to a negative selection step to eliminate non-specific sequences from the pool. Following the completion of the final 
round of SELEX aptamers can then be sequenced and characterised.
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The ability to generate aptamers against cell surface mark-
ers which are internalised via receptor mediated endocy-
tosis makes them an excellent platform for specific drug 
delivery. Currently, cytotoxic agents employed to treat 
malignancies are indiscriminate and non-specific, meaning 
they not only kill cancer cells but also healthy cells, leading 
to severe and dose-limiting side effects (Wang et al, 2012). 
In addition to this, the therapeutic efficiencies of these 
agents decreases throughout the treatment course as a 
result of chemo acquired resistance (Porciani et al, 2015). 
Doxorubicin (DOX) is one of the most widely employed 
chemotherapeutic agents for the treatment of several can-
cers, including lung and breast cancer, both which have 
a high incidence of metastasising to the brain (Table 1). 
The anticancer effect of DOX is the result of its ability to 
intercalate into DNA, disrupting replication and transcrip-
tion (Thorn et al, 2011; Yang et al, 2014). As aptamers form 
tertiary conformations with short double stranded non-
binding nucleic acid regions, they can be exploited to inter-
calate DOX, resulting in the development of a specific drug 
delivery vehicle (Famulok et al, 2007; Keefe et al, 2010; 
Zhou et al, 2017). This was first demonstrated in 2006 by 
Bagalkot et al who reported the specific delivery of DOX 
to prostate cancer cells utilising an aptamer which targets 
prostate specific membrane antigen expressed on prostate 
cancer cells (Bagalkot et al, 2006). Since then, the devel-
opment of aptamer DOX conjugates have been extensively 
reported (Bagalkot et al, 2006; Huang et al, 2009; Subra-
manian et al, 2012; Xu et al, 2013; Porciani et al, 2015; Yu 
et al, 2016a; Xiang et al, 2017). The overexpression of the 
membrane glycoprotein epithelial cell adhesion molecule 
(EpCAM) on a number of solid cancers with a high incidence 
of metastasising to the brain, makes it a highly attractive 
target for the treatment of BMs (Shigdar et al, 2011; Soysal 
et al, 2013). In 2017, Xiang et al reported the development 
of an aptamer-DOX conjugate targeting EpCAM (Xiang et al, 
2017). Through modifying the original EpCAM aptamer to 
increase the length of the double stranded region, they 
were able to intercalate 2–3 molecules of DOX per aptamer 
(Xiang et al, 2017). Treatment of tumour bearing xenograft 
mice with the aptamer-DOX conjugates compared to DOX 
alone, resulted in a 3-fold inhibition of tumour growth and 
a significantly longer survival time (Xiang et al, 2017). As 
DOX is intercalated into the aptamer structure, this delivery 
method is only effective for chemotherapeutics with a simi-
lar mechanism of action.
Given their nucleic acid structure, aptamers can easily be 
modified with linkers to allow attachment of drugs not 
capable of direct intercalation. The covalent conjugation of 
these drugs indirectly to the aptamer via chemical linkers 
makes them unlikely to influence specificity and sensitiv-
ity. Through the direct conjugation of methotrexate, a drug 
used to treat acute myeloid leukaemia, to a DNA aptamer 
targeting CD117 via an amine coupling reaction, Zhao et al 
were able to demonstrate a significantly increased cyto-
toxic effect compared to methotrexate alone (Zhao et al, 
2015). More recently, through enzymatic or chemical con-
jugation, Yoon et al conjugated gemcitabine and 5-fluo-
rouracil to the pancreatic cancer RNA aptamer P19 (Yoon 
et al, 2017). Within this study the aptamer-drug conjugates 
were shown to be internalised and induce DNA damage, 
even in a gemcitabine resistant cell line (Yoon et al, 2017). 
While these aptamer-drug conjugates do not target cancers 
with a high incidence of metastasising to the brain, or have 
the ability to transcytose the BBB, the drugs described can 
easily be attached to aptamers which do.
Over the past decade nanoparticles have been developed 
as anti-cancer drug delivery vehicles given their high load-
ing drug capacity. While alone these vehicles lack specific 
targeting, once combined with an active targeting mech-
anism, such as aptamers, highly specific drug delivery 
vehicles are developed. This has recently been explored 
through the functionalisation of drug encapsulating biode-
gradable polymeric nanoparticles for glioblastoma target-
ing (Monaco et al, 2017). Platelet derived growth factor 
receptor β (PDGFRβ) is a highly attractive target for glio-
blastoma treatment given its expression in different glio-
blastoma subtypes and high expression on endothelial 
cells of the BBB (Kim et al, 2012). Through conjugating an 
aptamer targeting PDGFRβ with the drug encapsulating 
nanoparticles, Monaco et al were able to develop an active 
targeting mechanism capable of crossing the BBB via recep-
tor mediated transcytosis and targeting glioblastoma cells 
(Monaco et al, 2017). A similar drug delivery vehicle to this 
could be developed for the treatment of BMs.
TRANSFERRIN RECEPTOR APTAMERS WITH THE 
POTENTIAL OF CROSSING THE BLOOD-BRAIN-BAR-
RIER
Ubiquitously expressed in normal cells at low levels and 
more highly expressed (approximately 100-fold up regu-
lation) in cells with a high proliferation rate and on the 
endothelium of the BBB, the TfR has become an ideal tar-
get for cancer diagnosis and treatment (Daniels et al, 2012).
Two methods exist in which this receptor can be targeted 
and influence cancer cell progression. The first involves 
blocking the natural function of the receptor, iron homeo-
stasis, which consequently leads to cancer cell death (Dan-
iels et al, 2012). The second is the use of the receptor as a 
ferrying system to deliver therapeutic molecules into can-
cerous cells (Figure 3D) (Wilner et al, 2012). Tf, the natu-
ral ligand of this receptor has been widely employed as a 
transport vector for this method (Elliott et al, 1988; Kratz 
et al, 1998; Singh et al, 1998). The near saturation of the 
TfR from endogenous Tf in physiological conditions limits 
the applicability of Tf as a transport vehicle, as in order 
to ensure adequate delivery of the therapeutic payloads 
exceedingly high levels would be required (Porciani et al, 
2014). Aptamers are a promising alternative to overcome 
this limitation given their ability to target different sites on 
the TfR and the possibility of generating them with higher 
affinities towards TfR than natural Tf (Porciani et al, 2014).
In 2008, Chen et al reported the development of DNA and 
RNA aptamers that selectively recognise the extracellular 
domain of the mouse TfR (Chen et al, 2008). Originally 
64 nucleotides long, Chen and colleagues truncated the 
selected DNA aptamer, GS24, to 50 nucleotides while still 
maintaining sensitivity and selectivity (Chen et al, 2008). 
Using the same aptamer, Porciani et al found that through 
mutating the aptamer sequence, affinity towards the 
mouse TfR was increased and the aptamer was capable 
of binding human TfR albeit with a lower affinity (Porciani 
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et al, 2014). During the development of new medicinal 
therapies, a fundamental problem which arises and hinders 
progression from bench top to clinical trials is the efficacy 
of the therapy within in vivo animal models (White et al, 
2001). Therefore, because the TfR aptamer generated by 
Porciani and colleagues cross reacts between mouse and 
human, it is highly attractive for further functionalisation 
and to be developed for therapeutic application. While 
being cross reactive, this aptamer was selected using 
unmodified nucleotides, making it highly susceptible to 
nuclease degradation (Chen et al, 2008). In 2012, Wilner at 
al. reported the generation of nuclease stabilised aptamers 
which target the human TfR and are readily internalised by 
human cell lines (Wilner et al, 2012).
DEVELOPING A BIFUNCTIONAL APTAMER TO TARGET 
BRAIN METASTASES
The concept of developing aptamers for the treatment 
of brain disorders is not new. There have been numerous 
reports of aptamers generated for the targeted treatment 
of specific brain diseases such as glioblastoma and Alzhei-
mer’s disease (Ylera et al, 2002; Tannenberg et al, 2013; 
Aptekar et al, 2015; Esposito et al, 2016). While these 
aptamers have been shown to be highly specific for their 
target and demonstrated efficient cellular uptake, only one 
is capable of crossing the BBB alone as a result of its target, 
PDGFRβ, being overexpressed on the BBB and glioblastoma 
cells (Esposito et al, 2016). To overcome this restrictive 
barrier, through numerous rounds of in vivo selection, 
Cheng and colleagues generated an RNA brain penetrat-
ing aptamer known as A15 (Cheng et al, 2013). Through in 
vitro and in vivo characterisation, it was confirmed that the 
A15 aptamer possessed the ability to enter brain endothe-
lial cells under physiological conditions and in addition to 
this, could enter the brain parenchyma (Cheng et al, 2013). 
While the ability of this aptamer to enter the brain paren-
chyma is noteworthy, the aptamer has purely been gener-
ated to cross into the brain. Further functionalisation, such 
as drug attachment, or the addition of a second targeting 
mechanism, is required for this aptamer to be developed 
into an effective therapeutic.
The therapeutic potential of mono-specific nucleic acid 
aptamers can be further enhanced through the produc-
tion of bifunctional aptamers. Developed by fusing two 
aptamer binding sequences, these aptamers are designed 
by two different pathways. The first entails the fusion of two 
aptamers with independent binding activities. Generation 
in this manner broadens the limited recognition capability 
of mono-functional aptamers, a highly attractive property 
for cancer therapeutics (Zhu et al, 2012). In 2011, Min et al 
reported the development of a bifunctional aptamer based 
DOX delivery vehicle (Min et al, 2011). Through the con-
jugation of an RNA aptamer targeting PSMA positive cells, 
with a peptide aptamer specific for PSMA negative cells, 
DOX was synchronously delivered to two types of pros-
tate cancer cells and resultantly induced cell cytotoxicity, 
addressing the underlying problem of solid tumour het-
erogeneity (Min et al, 2011). Similarly, the following year a 
bifunctional aptamer targeting leukaemia subtypes, sgc8c-
sgda5a aptamer, was developed which elicited bi-specific 
cytotoxicity (Zhu et al, 2012). The second method involves 
the joining of two aptamer binding sequences in which the 
binding of the first aptamer influences the binding of the 
second (Le et al, 2013). Synthesis in this manner creates 
the possibility of delivering drug payloads to sites within 
the body which may not be accessible to drug alone due 
to restrictive transport mechanisms. However, as men-
tioned previously, modification of an aptamers sequence 
can negatively impact binding properties and therefore, 
some aptamers may be less tolerant to fusion with another 
sequence. Therefore re-characterisation following the for-
mation of bifunctional aptamers is essential.
Given the highly restrictive nature of the BBB, this method 
could be utilised to generate a bifunctional aptamer, which 
targets the TfR to transport chemotherapeutic agents 
across the barrier and specifically deliver them to BMs 
by targeting markers expressed on the cancer cell surface 
membrane. This method has been explored through the 
truncation and fusion of two aptamer sequences, one tar-
geting the TfR and the other targeting EpCAM (Figure 5) 
(Soysal et al, 2013; Macdonald et al, 2017). Fusion of the 
truncated sequences resulted in the generation of an 
aptamer which demonstrated specificity and sensitivity to 
both intended targets (Macdonald et al, 2017). Given the 
ubiquitous expression of TfR throughout the body, the abil-
ity of the aptamer to transcytose the BBB and its distribu-
tion in non-targeted tissues was investigated (Macdonald 
et al, 2017). From this, the ability of the aptamer to transcy-
tose the BBB was confirmed, with a percentage of injected 
dose 12 fold higher than the control sequence recorded in 
the brain 30minutes after administration (Macdonald et al, 
2017). As expected, aptamer accumulation in highly per-
fused organs, such as the liver and spleen, 30minutes after 
administration was high (Macdonald et al, 2017). Compared 
to this, retention at 60minutes was markedly lower, indi-
cating the measured levels at 30minutes are not likely the 
result of aptamer binding, but perfusion levels (Macdonald 
et al, 2017). When considering these results, it is impor-
tant to note the fact that they were measured in a healthy 
animal model, meaning the aptamer was targeting TfR on 
the BBB as well throughout the body. Further experimental 
work in a disease model needs to be conducted to gain an 
accurate representation of bio-distribution. Using the same 
model, aptamer distribution within the brain itself needs to 
be investigated, given TfR expression in healthy neuronal 
cells (Moos et al, 2000). The results thus far highlight the 
potential this aptamer has to be developed as an effective 
modality for overcoming the BBB, opening a new window 
for targeted drug delivery to the brain.
Given the ability to intercalate anthracycline chemothera-
peutics in aptamers structure, the bifunctional aptamer 
has the potential to be developed as a drug delivery vehicle 
without modification. The conjugation of a chemothera-
peutic drug to the bifunctional aptamer has numerous 
benefits, to both the patient and healthcare system. Firstly, 
the required concentration of the drug could be reduced, 
benefiting both the patient and healthcare system. Sec-
ondly, intercalation into the aptamers structure, would give 
them the ability to circumvent the BBB, a task alone they 
are incapable of. Furthermore, the effective targeting of the 
aptamer to tumour cells and subsequent internalisation via 
endocytosis would reduce the indiscriminate side effects 
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of the agent and increase drug concentration. While there 
is the potential for side effects in non-targeted tissues, 
compared to the effects experienced by patients following 
current treatment regimens, the extent of these would be 
considerably reduced.
CONCLUSIONS
While the landscape of cancer treatment has drastically 
changed over the last few decades, improving primary 
malignancy survival rates, the incidence of BMs is still 
increasing. This is the result of treatment advances increas-
ing the length of patient’s lives, which in turn allows a 
greater period of time for metastasis to occur. Treatment of 
these metastatic malignancies is complicated by the pres-
ence of the BBB, which isolates the brain microenvironment 
from systemic circulation by strictly regulating the passage 
of molecules. This presents a problem as practically all large 
molecules and 98% of small molecules are prevented from 
crossing the BBB, necessitating the need for more effec-
tive therapeutics (Gabathuler, 2010). Numerous strategies 
have been developed for circumventing the barrier, such as 
direct injection or barrier disruption to increase permeabil-
ity, but each strategy poses great risk to the patient (Debin-
ski et al, 2009; Lassaletta et al, 2009; Wu et al, 2014).
A promising technique being developed to reduce these 
risks and overcome the BBB is the development of thera-
peutics modalities which are substrates for influx trans-
porters present on endothelial cell membranes. Given their 
specificity, safety profile and stability, nucleic acid based 
therapeutics are ideal for this purpose. The development of 
Figure 5. Schematic representation of the bifunctional aptamer mechanism. While in systemic circulation the aptamer binds to the 
TfR on the apical membrane where it is then invaginated into an intracellular vesicle. The aptamer is then transcytosed through the 
endothelial cell and released into the brain microenvironment where it targets EpCAM expressed on the metastatic tumour cells. 
The TfR is then recycled back to the apical membrane.
25
©The Author(s) | Aptamers | 2018 | Volume 2 | 15–27 | OPEN ACCESS | ISSN 2514-3247
a targeted delivery system capable of crossing the BBB and 
specifically delivering chemotherapeutic agents to BMs has 
the potential to significantly improve patient survival and 
quality of life.
Furthermore, through specially targeting the cancerous 
cells and sparing the healthy brain tissue, this system will 
reduce the concentration of drug required for treatment, 
further reducing the associated side effects and addition-
ally reducing healthcare costs for the patient and the pub-
lic healthcare system. In conclusion, the development of 
bifunctional aptamers for the treatment of BMs shows 
great promise, however, further investigation is required 
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